Double maintains 1 strategies that include BNTX - BioNTech SE
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 53.07% | $40.65M | 0.5% |
IBB | 51.61% | $5.22B | 0.45% |
BBH | 50.24% | $327.42M | 0.35% |
XBI | 50.21% | $4.85B | 0.35% |
FBT | 48.37% | $994.71M | 0.56% |
PBE | 45.23% | $214.12M | 0.58% |
QQQJ | 44.52% | $610.08M | 0.15% |
ARKG | 43.71% | $944.78M | 0.75% |
PID | 42.97% | $831.69M | 0.53% |
DSTL | 41.27% | $1.88B | 0.39% |
VB | 41.20% | $62.13B | 0.05% |
SMOT | 41.12% | $363.89M | 0.49% |
VLUE | 40.91% | $6.44B | 0.15% |
VBK | 40.76% | $18.33B | 0.07% |
NUSC | 40.73% | $1.14B | 0.31% |
MOAT | 40.70% | $13.02B | 0.47% |
ISCG | 40.70% | $645.00M | 0.06% |
SMMD | 40.67% | $1.46B | 0.15% |
FXD | 40.52% | $334.25M | 0.61% |
SIZE | 40.51% | $323.03M | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | -11.39% | $27.05M | -37.35% | 0.00% |
LITB | -9.71% | $21.28M | -72.45% | 0.00% |
CBOE | -5.14% | $22.95B | +20.67% | 1.12% |
K | -3.03% | $28.49B | +32.17% | 2.77% |
FMTO | -3.03% | $45.74M | -99.96% | 0.00% |
TPB | -2.95% | $1.29B | +113.31% | 0.40% |
CYCN | -2.56% | $9.37M | +2.39% | 0.00% |
WST | -2.35% | $15.14B | -40.50% | 0.39% |
OPCH | -1.77% | $5.32B | +8.88% | 0.00% |
NEUE | -1.63% | $62.05M | +13.56% | 0.00% |
PPC | -1.59% | $11.21B | +41.54% | 0.00% |
MVO | -1.23% | $66.70M | -38.82% | 21.64% |
MQ | -1.16% | $2.34B | -11.50% | 0.00% |
AQB | -0.84% | $2.96M | -61.58% | 0.00% |
COR | -0.74% | $55.43B | +28.90% | 0.56% |
CME | -0.70% | $98.74B | +28.80% | 3.84% |
VHC | -0.49% | $34.69M | +74.89% | 0.00% |
HRB | -0.23% | $7.60B | +7.02% | 2.55% |
INSM | -0.18% | $12.24B | +167.81% | 0.00% |
NOC | -0.14% | $67.51B | -0.35% | 1.76% |
Current Value
$92.781 Year Return
Current Value
$92.781 Year Return
Finnhub
Presenter SpeechHelmut Jeggle Has held senior positions as leading global companies. Most recently, he was CFO of the Global Biomedical Research Organization, Novartis Medical research, a
Finnhub
Deutsche Bank analyst Emmanuel Papadakis maintains his Buy rating on the stock. The target price is still set at USD 140.
Finnhub
The legal battle for dominance in the mRNA therapeutic space has intensified in 2025. As companies scale their platforms beyond COVID-19, patents covering mRNA constructs, delivery systems, and...
Finnhub
UBS analyst Eliana Merle maintains his Neutral opinion on the stock. The target price remains set at USD 115.
SeekingAlpha
BioNTech maintains â¬15.85B reserves as COVID revenues fall and R&D grows.
Finnhub
In his latest research note, analyst Harry Gillis confirms his positive recommendation. The broker Berenberg is keeping its Buy rating. The target price is still set at USD 130.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MRNA | 53.59% | $9.15B | -82.18% | 0.00% |
CVAC | 47.90% | $771.16M | -1.58% | 0.00% |
NVAX | 46.70% | $1.02B | -56.32% | 0.00% |
ARCT | 45.26% | $315.68M | -61.84% | 0.00% |
XNCR | 42.34% | $583.60M | -63.49% | 0.00% |
PFE | 41.64% | $128.49B | -21.85% | 7.56% |
EMN | 41.23% | $9.38B | -18.81% | 4.07% |
RCKT | 41.08% | $724.54M | -71.26% | 0.00% |
BC | 39.49% | $3.42B | -36.07% | 2.42% |
RY | 39.48% | $176.26B | +17.73% | 3.32% |
IMNM | 39.47% | $696.10M | -44.44% | 0.00% |
DNLI | 38.97% | $2.06B | -30.04% | 0.00% |
KYMR | 38.56% | $1.95B | -15.67% | 0.00% |
JLL | 38.53% | $11.18B | +13.49% | 0.00% |
DMRC | 38.35% | $289.87M | -46.16% | 0.00% |
CNI | 38.29% | $67.85B | -14.57% | 2.27% |
AVY | 37.88% | $14.22B | -19.02% | 1.93% |
SITE | 37.80% | $5.50B | -19.85% | 0.00% |
HD | 37.69% | $376.33B | +10.47% | 2.39% |
MGNX | 37.50% | $97.16M | -69.92% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | -0.09% | $25.35M | +93.08% | 0.00% |
ADBE | -0.12% | $172.48B | -16.19% | 0.00% |
NOC | -0.14% | $67.51B | -0.35% | 1.76% |
INSM | -0.18% | $12.24B | +167.81% | 0.00% |
HRB | -0.23% | $7.60B | +7.02% | 2.55% |
VHC | -0.49% | $34.69M | +74.89% | 0.00% |
MKTX | 0.64% | $8.01B | -1.42% | 1.39% |
CME | -0.70% | $98.74B | +28.80% | 3.84% |
COR | -0.74% | $55.43B | +28.90% | 0.56% |
GORV | 0.76% | $15.42M | -96.17% | 0.00% |
AQB | -0.84% | $2.96M | -61.58% | 0.00% |
SOHU | 0.99% | $330.12M | -9.26% | 0.00% |
MQ | -1.16% | $2.34B | -11.50% | 0.00% |
PRA | 1.20% | $1.19B | +58.17% | 0.00% |
CL | 1.21% | $72.64B | -5.18% | 2.25% |
CYD | 1.22% | $643.06M | +106.88% | 2.24% |
MVO | -1.23% | $66.70M | -38.82% | 21.64% |
MSIF | 1.27% | $715.25M | +28.42% | 7.05% |
SANA | 1.38% | $385.70M | -80.00% | 0.00% |
GREE | 1.48% | $15.12M | -58.87% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | 0.07% | $127.42M | 0.23% |
SGOV | -0.15% | $45.91B | 0.09% |
DBE | -0.21% | $48.48M | 0.77% |
UTWO | -0.35% | $387.71M | 0.15% |
VGSH | 0.41% | $22.38B | 0.03% |
IBTH | 0.42% | $1.53B | 0.07% |
CARY | 0.44% | $347.36M | 0.8% |
SHYM | 0.56% | $322.93M | 0.35% |
CMBS | 0.67% | $427.55M | 0.25% |
STPZ | -0.74% | $446.46M | 0.2% |
USO | 0.81% | $956.18M | 0.6% |
BNO | 0.93% | $86.13M | 1% |
USL | 1.08% | $41.76M | 0.85% |
IBMN | 1.13% | $446.12M | 0.18% |
LDUR | -1.26% | $849.09M | 0.5% |
TBLL | -1.27% | $2.46B | 0.08% |
BILZ | -1.35% | $876.85M | 0.14% |
SPTS | -1.47% | $5.76B | 0.03% |
UGA | -1.62% | $73.47M | 0.97% |
TBIL | -1.69% | $5.76B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -27.96% | $361.41M | 1.43% |
VIXY | -26.30% | $109.64M | 0.85% |
TAIL | -26.13% | $140.49M | 0.59% |
IVOL | -14.85% | $353.94M | 1.02% |
USDU | -12.52% | $173.44M | 0.5% |
UUP | -10.20% | $292.27M | 0.77% |
CTA | -9.66% | $1.05B | 0.76% |
ULST | -9.44% | $637.77M | 0.2% |
FTSD | -8.62% | $212.46M | 0.25% |
CLIP | -7.83% | $1.50B | 0.07% |
TPMN | -6.99% | $31.54M | 0.65% |
KMLM | -6.01% | $188.32M | 0.9% |
CANE | -5.77% | $10.71M | 0.29% |
GBIL | -4.68% | $6.17B | 0.12% |
BILS | -4.07% | $3.96B | 0.1356% |
XONE | -3.82% | $603.24M | 0.03% |
FMF | -3.74% | $153.73M | 0.95% |
BIL | -3.52% | $45.95B | 0.1356% |
KCCA | -3.24% | $97.18M | 0.87% |
XHLF | -2.94% | $1.46B | 0.03% |